Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Roche Media News
Get the latest updates from Roche Media News directly as they happen.
Follow now 290 followers
Latest posts
Last updated about 12 hours ago
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
about 12 hours ago
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza...
FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
4 days ago
OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without...
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
7 days ago
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options...
Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation
9 days ago
Switzerland’s most innovative research and development center underscores Roche’s long-term investment in...
Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
15 days ago
New Phase II data show vast majority of patients experiencing no relapses...
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
24 days ago
With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce...
Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak
about 1 month ago
Roche is committed to supporting all those working to overcome the mpox...
European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)
about 2 months ago
Approval is based on data from two Phase III studies in branch...
Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care
about 2 months ago
The acquisition of LumiraDx’s Point of Care technology received all required antitrust...
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
about 2 months ago
Group sales were up by 5%1 at constant exchange rates (CER) (stable...
New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
2 months ago
Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as...
Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study
2 months ago
More than 90% of patients had absence of DME after four years...